Problematic patent settlements continue to fall in number, says European Commission
This article was originally published in SRA
Originator and generic manufacturers are entering into fewer "potentially problematic" settlements that violate antitrust regulations and delay market entry of generic medicines, a new monitoring exercise by the European Commission has revealed1.
You may also be interested in...
While information sharing is key to cross-country collaborations on access to medicines and can lead to major benefits, it is hard to sell to political leaders and the media, says a report from the World Health Organization’s regional office for Europe.
The European Commission says it will publish its review of the EU orphan drug legislation in the coming days.
The UK has formally withdrawn its ratification of the Unified Patent Court Agreement, adding to the uncertainty over its future.